Videos Library
From PMPRB reforms to pCPA to National Pharmacare? Where is Canada heading when it comes to pricing and reimbursement of pharmaceuticals?
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Canada
Overview
- Impact of PMPRB proposed price reforms – new reference countries, HTA to set price thresholds, risk based assessments.
- pan Canadian Pharmaceutical Alliance (pCPA) – more structure, guidelines, for negotiating public payer listing agreements / access schemes.
- Implementation of National Pharmacare – proposals for “public only” national pharmacare program are again being considered seriously by Federal advisory committee.
- Insurers for private drug plans seek to maintain market but gain access to pCPA rebates.
- Outlook and implications for Canadian pricing and market access.
Speaker
Dylan Lamb-Palmer
Manager, Pricing and Data Analytics
PDCI Market Access, Canada
Subscribe or unlock this video to download the presentation slides. If you already have an account, please log in.
REMINDER
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.
Sponsor
